- Home
- CHRW vs GMAB Comparison
CHRW vs GMAB Comparison
Compare CHRW & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRW
- GMAB
- Stock Information
- Founded
- CHRW 1905
- GMAB 1999
- Country
- CHRW United States
- GMAB Denmark
- Employees
- CHRW N/A
- GMAB N/A
- Industry
- CHRW Oil Refining/Marketing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CHRW Consumer Discretionary
- GMAB Health Care
- Exchange
- CHRW Nasdaq
- GMAB Nasdaq
- Market Cap
- CHRW 14.8B
- GMAB 17.4B
- IPO Year
- CHRW 1997
- GMAB N/A
- Fundamental
- Price
- CHRW $129.06
- GMAB $29.03
- Analyst Decision
- CHRW Buy
- GMAB Strong Buy
- Analyst Count
- CHRW 21
- GMAB 7
- Target Price
- CHRW $132.15
- GMAB $41.17
- AVG Volume (30 Days)
- CHRW 1.4M
- GMAB 3.1M
- Earning Date
- CHRW 10-29-2025
- GMAB 11-06-2025
- Dividend Yield
- CHRW 1.97%
- GMAB N/A
- EPS Growth
- CHRW 58.22
- GMAB 77.72
- EPS
- CHRW 4.40
- GMAB 21.62
- Revenue
- CHRW $17,012,580,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- CHRW N/A
- GMAB $24.25
- Revenue Next Year
- CHRW $3.64
- GMAB $16.29
- P/E Ratio
- CHRW $28.66
- GMAB $13.36
- Revenue Growth
- CHRW N/A
- GMAB 32.97
- 52 Week Low
- CHRW $84.68
- GMAB $17.24
- 52 Week High
- CHRW $138.00
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- CHRW 44.27
- GMAB 43.12
- Support Level
- CHRW $125.35
- GMAB $29.57
- Resistance Level
- CHRW $130.16
- GMAB $30.24
- Average True Range (ATR)
- CHRW 2.96
- GMAB 0.65
- MACD
- CHRW -0.52
- GMAB -0.60
- Stochastic Oscillator
- CHRW 26.84
- GMAB 0.59
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.